ArticleAnnals of surgical oncology2026
Hepatic Recurrence Rate Based on Extent of Adjuvant Floxuridine Exposure After Resection of Colorectal Liver Metastases.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundHepatic artery infusion (HAI) chemotherapy improves hepatic recurrence rates and survival for patients with colorectal liver metastases (CRLM) in the adjuvant setting. Dose reductions of HAI floxuridine (FUDR) are common due to hepatotoxicity. The impact of these dose adjustments on patient outcomes is unclear.
methodsThis study retrospectively analyzed patients who underwent adjuvant HAI pump placement for CRLM between January 2000 and October 2017. The study enrolled only patients intended to receive six cycles of FUDR. Hepatic recurrence and overall survival (OS) were correlated with the number of FUDR cycles and dose density, defined as the actual FUDR dose received divided by the expected total during six cycles.
resultsThe study identified 344 patients who met the inclusion criteria. Of these 344 patients, 173 received up to four cycles of FUDR and 171 received > 4 cycles. The median dose density was 0.42 (range, 0.17-1.13). Competing risk analysis of the two groups showed no difference in risk for liver recurrence (p = 0.357). Neither the cycles of FUDR received (hazard ratio [HR], 0.93; p = 0.237) nor the FUDR dose density (HR, 1.26; p = 0.631) was associated with hepatic recurrence in the univariable analysis. Dose density was not associated with improved OS (HR, 1.35; p = 0.486), although in the multivariable analysis, increased FUDR cycles were associated with improved OS (HR, 0.86; p = 0.005).
conclusionsIn adjuvant HAI therapy for CRLM, neither the number of FUDR cycles nor the dose density of FUDR is associated with hepatic recurrence.
Indexed as
Identifiers
41165901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.